Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Phillip S Pang

Showing results (11-20 of 46) with videos related to

Pageof 5
Sort By:
Lancet (London, England)|November 12, 2013
Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trialEric Lawitz, Fred F Poordad, Phillip S Pang, et al.
Antimicrobial Agents and Chemotherapy|August 8, 2012
Characterization of resistance to the protease inhibitor GS-9451 in hepatitis C virus-infected patientsHadas Dvory-Sobol, Kelly A Wong, Karin S Ku, et al.
Hepatology (Baltimore, Md.)|April 8, 2015
Ledipasvir-sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimensDavid Wyles, Paul Pockros, Giuseppe Morelli, et al.
Gastroenterology|November 23, 2013
Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infectionEdward J Gane, Catherine A Stedman, Robert H Hyland, et al.
Hepatology (Baltimore, Md.)|May 1, 2012
Randomized, placebo-controlled trial of tenofovir disoproxil fumarate in adolescents with chronic hepatitis BKaren F Murray, Leszek Szenborn, Jacek Wysocki, et al.
Nature|July 8, 2021
After the pandemic: perspectives on the future trajectory of COVID-19Amalio Telenti, Ann Arvin, Lawrence Corey, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 27, 2016
Successful Re-treatment of Hepatitis C Virus in Patients Coinfected With HIV Who Relapsed After 12 Weeks of Ledipasvir/SofosbuvirCurtis Cooper, Susanna Naggie, Michael Saag, et al.
Antiviral Therapy|February 19, 2016
On-treatment HCV RNA in patients with varying degrees of fibrosis and cirrhosis in the SOLAR-1 trialTania M Welzel, K Rajender Reddy, Steven L Flamm, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 22, 2024
A Randomized, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of VIR-2482 in Healthy Adults for Prevention of Influenza A Illness (PENINSULA)Susanna K Tan, Deborah Cebrik, David Plotnik, et al.
Antiviral Therapy|October 7, 2015
The safety and efficacy of ledipasvir/sofosbuvir for the treatment of a nosocomial outbreak of HCV in patients with significant cardiovascular diseaseTracey G Simon, Arthur Y Kim, Luisa M Stamm, et al.
Pageof 5

Showing results (11-20 of 46) with videos related to

Sort By:
Pageof 5
Lancet (London, England)|November 12, 2013
Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trialEric Lawitz, Fred F Poordad, Phillip S Pang, et al.
Antimicrobial Agents and Chemotherapy|August 8, 2012
Characterization of resistance to the protease inhibitor GS-9451 in hepatitis C virus-infected patientsHadas Dvory-Sobol, Kelly A Wong, Karin S Ku, et al.
Hepatology (Baltimore, Md.)|April 8, 2015
Ledipasvir-sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimensDavid Wyles, Paul Pockros, Giuseppe Morelli, et al.
Gastroenterology|November 23, 2013
Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infectionEdward J Gane, Catherine A Stedman, Robert H Hyland, et al.
Hepatology (Baltimore, Md.)|May 1, 2012
Randomized, placebo-controlled trial of tenofovir disoproxil fumarate in adolescents with chronic hepatitis BKaren F Murray, Leszek Szenborn, Jacek Wysocki, et al.
Nature|July 8, 2021
After the pandemic: perspectives on the future trajectory of COVID-19Amalio Telenti, Ann Arvin, Lawrence Corey, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 27, 2016
Successful Re-treatment of Hepatitis C Virus in Patients Coinfected With HIV Who Relapsed After 12 Weeks of Ledipasvir/SofosbuvirCurtis Cooper, Susanna Naggie, Michael Saag, et al.
Antiviral Therapy|February 19, 2016
On-treatment HCV RNA in patients with varying degrees of fibrosis and cirrhosis in the SOLAR-1 trialTania M Welzel, K Rajender Reddy, Steven L Flamm, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 22, 2024
A Randomized, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of VIR-2482 in Healthy Adults for Prevention of Influenza A Illness (PENINSULA)Susanna K Tan, Deborah Cebrik, David Plotnik, et al.
Antiviral Therapy|October 7, 2015
The safety and efficacy of ledipasvir/sofosbuvir for the treatment of a nosocomial outbreak of HCV in patients with significant cardiovascular diseaseTracey G Simon, Arthur Y Kim, Luisa M Stamm, et al.
Pageof 5